Grant of Interim Extension of the Term of U.S. Patent No. 4,850,962; Esteem (Totally Implantable Hearing System), 34897 [E6-9494]
Download as PDF
Federal Register / Vol. 71, No. 116 / Friday, June 16, 2006 / Notices
patent term under 35 U.S.C. 156(d)(5) is
appropriate.
A third interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,591,585 is granted for a
period of one year from the expiration
date of the patent, i.e., until June 18,
2007.
Dated: June 12, 2006.
Jon W. Dudas
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9489 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0033]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,585,597;
´
ANTHELIOS SP (HELIOBLOCK SX
Cream) (Mexoryl SX (Ecamsule))
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a fourth one-year interim extension of
the term of U.S. Patent No. 4,585,597.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On May 16, 2006, patent owner, L
Oreal S.A., timely filed an application
under 35 U.S.C. 156(d)(5) for a fourth
subsequent interim extension of the
term of U.S. Patent No. 4,585,597. The
patent claims the active ingredient
Mexoryl SX (ecamsule), in the human
drug product ANTHELIOS SP
(HELIOBLOCK SX Cream), a method of
wwhite on PROD1PC61 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
18:25 Jun 15, 2006
Jkt 208001
use of the active ingredient, and a
method of manufacturing the active
ingredient. The application indicates,
and the Food and Drug Administration
has confirmed, that a New Drug
Application for the human drug product
Mexoryl SX (ecamsule) has been filed
and is currently undergoing regulatory
review before the Food and Drug
Administration for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional year as
required by 35 U.S.C. 156(d)(5)(B).
Because it is apparent that the
regulatory review period will continue
beyond the extended expiration date of
the patent (June 16, 2006), interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate. A fourth
interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,585,597 is granted for a period of one
year from the extended expiration date
of the patent, i.e., until June 16, 2007.
Dated: June 12, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9490 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0019]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,850,962; Esteem
(Totally Implantable Hearing System)
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a one-year interim extension of the term
of U.S. Patent No. 4,850,962.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
34897
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 31, 2006, patent owner,
Envoy Medical Corporation, timely filed
an application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
U.S. Patent No. 4,850,962. The patent
claims the medical device Esteem
(totally implantable hearing system).
The application indicates that an
Investigational Device Exemption for
the medical device Esteem has been
filed and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the original
expiration date of the patent (July 25,
2006), interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,850,962 is granted for a period of one
year from the original expiration date of
the patent, i.e., until July 25, 2007.
SUPPLEMENTARY INFORMATION:
Dated: June 12, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9494 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–16–P
COMMODITY FUTURES TRADING
COMMISSION
Sunshine Act Meeting
TIME AND DATE:
11 a.m., Friday, July 7,
2006.
1155 21st St., NW., Washington,
DC, 9th Floor Commission Conference
Room.
STATUS: Closed.
MATTERS TO BE CONSIDERED: Surveillance
Matters.
PLACE:
E:\FR\FM\16JNN1.SGM
16JNN1
Agencies
[Federal Register Volume 71, Number 116 (Friday, June 16, 2006)]
[Notices]
[Page 34897]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9494]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2006-0019]
Grant of Interim Extension of the Term of U.S. Patent No.
4,850,962; Esteem (Totally Implantable Hearing System)
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension
of the term of U.S. Patent No. 4,850,962.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 31, 2006, patent owner, Envoy Medical Corporation, timely
filed an application under 35 U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 4,850,962. The patent claims the medical
device Esteem (totally implantable hearing system). The application
indicates that an Investigational Device Exemption for the medical
device Esteem has been filed and is currently undergoing regulatory
review before the Food and Drug Administration for permission to market
or use the product commercially.
Review of the application indicates that except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review
period will continue beyond the original expiration date of the patent
(July 25, 2006), interim extension of the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,850,962 is granted for a period of one year from the
original expiration date of the patent, i.e., until July 25, 2007.
Dated: June 12, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property andDirector of
the United States Patent and Trademark Office.
[FR Doc. E6-9494 Filed 6-15-06; 8:45 am]
BILLING CODE 3510-16-P